Analysts have raised their target price for Fosun International slightly, from $5.67 to $5.68. They cite minor adjustments in key valuation assumptions as the reason for this change.
What's in the News
- Fosun International will hold a Special/Extraordinary Shareholders Meeting on October 23, 2025, in Shanghai to consider the adoption of the 2025 H share RSU scheme for Fosun Pharma and related authorizations (Key Developments).
- Between January 1 and June 5, 2025, the company repurchased 31,082,500 shares for HKD 126.31 million, completing a total buyback of 41,310,000 shares under its ongoing program announced in August 2024 (Key Developments).
Valuation Changes
- The Fair Value Estimate has increased slightly, moving from HK$5.67 to HK$5.68.
- The Discount Rate has risen moderately, from 12.89% to 13.02%.
- Revenue Growth projections remain virtually unchanged at approximately 6.72%.
- Net Profit Margin forecasts show a negligible decrease, shifting from 2.49% to 2.49%.
- The future Price-to-Earnings (P/E) ratio has risen marginally, from 11.02x to 11.04x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.